A new study links type 2 diabetes drug Onglyza (saxagliptin), an incretin mimetic that stimulates the pancreas to make more insulin after a patient eats a meal, to a small but significant increase for acute pancreatitis. The results of the study, lead by Rury R.…
Zofran manufacturer GlaxoSmithKline (GSK) wants the court to dismiss hundreds of Zofran birth defect lawsuits. Though a number of studies have linked Zofran (ondansetron), when taking by expectant moms, to an increased risk of birth defects, the company maintains that there is insufficient evidence
On December 28, 2015, another Xarelto lawsuit joined the centralized litigation in the Eastern District of Louisiana. The plaintiff, a resident of New Jersey, brought claims against manufacturers Janssen Pharmaceuticals, parent company Johnson & Johnson, and Bayer Pharma AG. There are currently over
For about a year-and-a-half now, federally filed testosterone therapy treatment lawsuits have been proceeding in the centralized litigation in Northern District of Illinois. About 3,500 cases are currently pending there, with most claiming that products like AndroGel, Testim, Androderm, and Axiron c
A Chicago woman has filed a new Onglyza lawsuit, claiming manufacturer AstraZeneca is liable for her mother’s death. The case was filed on October 29, 2015, in the Cook County Circuit Court. The plaintiff seeks in excess of $50,000 in damages. Plaintiff Claims AstraZeneca Failed…
About a year ago, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federal Xarelto lawsuits into one court in the Eastern District of Louisiana. Since then, parties have been involved in pre-trial proceedings, including discovery and selection of potential bellwether cases
Manufacturers of the type 2 diabetes drug Invokana (canagliflozin) are facing another Invokana lawsuit recently filed in the Eastern District of California. The plaintiff, a resident of California, brings claims against Janssen Pharmaceuticals and parent company Johnson & Johnson for failing to warn
Onglyza (saxagliptin) is a type 2 diabetes medication that was approved by the FDA in 2009. It belongs to a class of drugs known as “incretin mimetics,” which stimulate the pancreas to make more insulin after the patient eats a meal, in order to keep…
On September 10, 2015, plaintiffs filed a new class action lawsuit against the manufacturers of diabetes drug Invokana: Janssen Pharmaceuticals and parent company Johnson & Johnson. Representative plaintiff Rosalba Joudry, a resident of Ontario, filed the case on behalf of all persons in Canada who…
The FDA-approved type 2 diabetes medication Invokana (canagliflozin) first came on the market in March 2013. Now, only a little over two years later, the medication has been linked to a number of dangerous side effects, including kidney failure, diabetic ketoacidosis, bone fractures, and more.…
On July 17, 2015, plaintiffs from Massachusetts filed a new Zofran lawsuit in the U.S. District Court of the District of Massachusetts. They claim that after the mother took Zofran during her pregnancy, she gave birth to a baby boy who suffered from serious birth…
In May 2015, the Food and Drug Administration (FDA) warned doctors and patients that certain types of type 2 diabetes drugs, including Invokana (canagliflozin), could cause diabetic ketoacidosis (DKA) in some patients. This is a serious condition in which the blood becomes too acidic, and…
